Inflammatory Diseases

We are developing degraders of Phosphodiesterase 4 (PDE4), a validated target for auto-immune and inflammatory diseases such as psoriasis. Our first-in-class degraders are highly selective for PDE4 degradation and have shown greater potency than PDE4 inhibitors in terms of inhibition of key cytokines such as TNF-α, IFN-γand IL-1β in preclinical models.